Any small biopharma knows the importance of collaborating or partnering with larger companies and academic institutions. But where do you start, and who should be involved? And what kind of risk should you take on?
Soligenix is a late-stage biopharmaceutical company focused on rare diseases. The company’s president and CEO discusses how government grants and contracts can be one way to help fund research.
As the biotech sector in the U.S. continues to grow, it is doing so not just in hubs, but in smaller places like New Hampshire — where some of the state’s biopharma entrepreneurs say: “Smaller is better.”
We also sold our antibody drug candidate to Novartis in 2014 for another $5 million. We did everything we could to survive.
Now is the time to develop a novel financial instrument which will provide risk transfer, transparency, and more certainty. A futures market in healthcare is a product whose time has come.
As life sciences asset managers, our evaluation of the life science capital markets for the second quarter of 2017 is one of confidence, mediated by prudent caution. Our view has been based on a confluence of subjective and objective factors.
A Nevada woman’s death in 2016 from an untreatable bacterial infection called attention to the possibility of an “antibiotic apocalypse,” when even the most deadly bacterial strains will prove resistant to all available antibiotics. “Antibiotic development is not keeping pace with the emergence of antibiotic-resistant bacterial strains,” said Kevin Outterson, executive director of the new global public-private partnership, Combatting Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X).
IP due diligence standards need to be continuously updated to stay current, especially, as biopharma companies increasingly pursue high-stakes, IP-intensive deals in which an overlooked IP issue can undermine the entire value of such a transaction. The following are the five questions you must ask in corporate transactions regarding IP due diligence.
It is increasingly rare that early-stage compounds or platform technologies are acquired without demonstration of clinical effect. Many years ago you could get funding for an idea, a piece of data, or a novel platform. With little exaggeration, funding could be generally raised as long as there was promise and the ability to tell a story, or until the concept was fully disproven.
There is a serious push to make Texas the “Third Coast” of biotech and Austin, in particular, a new hub for the industry.